US5100668A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Controlled release systems containing heparin and growth factors
Assignee: Massachusetts Institute of Technology
•
Filing: 1988-06-14
•
Granted: 1992-03-31
•
Expires: 2008-06-14
Abstract
Abstract A system for stabilizing fibroblast-derived growth factors, maintaining their bioactivity over a prolonged period of time and controllably releasing them for use is disclosed. The system uses growth factors bound to biocompatible substrates via heparin or heparin derived compounds to maintain the bioactivity of the growth factors. A growth factor bound to a heparin coated substrate can be used independently as a controlled release device, or can be incorporated into a reservoir or matrix type controlled release devices to further enhance the controlled release properties. The stabilized growth factors can be implanted into a patient, thereby providing a means for producing an in vivo controlled release of a growth factor to the patient.
Inventors
- 👤 Elazer R. Edelman
- 👤 Robert S. Langer
- 👤 Michael Klagsburn
- 👤 Edith Mathiowitz
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 13:42
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/48; A61K9/50; A61K9/5005; A61K9/5021; A61K9/5036; A61K38/00; A61K38/16; A61K38/17; A61K38/18; A61K38/1825; A61K47/00; A61K47/50; A61K47/51; A61K47/56; A61K47/61; A61K9/14; A61K9/16; A61K9/167; Y; Y10; Y10S; Y10S530/00; Y10S530/81; Y10S530/812; Y10S530/813; Y10S530/815; Y10S530/816
Claims Analysis
Total Claims: 13
Claim 1
Independent Claim
38 words
A device for controlling the release rate of a fibroblast cross-linked dextran derived growth factor which comprises a substrate material having heparin or heparin sulfate bound thereto and the growth factor bound to the heparin or heparin sulfate.
Claim 2
Independent Claim
38 words
A device for controlling the release rate of a fibroblast cross-linked dextran derived growth factor which comprises a substrate material having heparin or heparin sulfate bound thereto and the growth factor bound to the heparin or heparin sulfate.
Claim 3
Dependent Claim
15 words
A device as in claim 1 wherein the substrate of cross-linked dextran material comprises beads.
Claim 4
Dependent Claim
14 words
A device as in claim 1 wherein said device further comprises an encapsulation means.
Claim 5
Dependent Claim
15 words
A device as in claim 3 wherein the encapsulation means comprises a sodium alginate envelope.
Claim 6
Dependent Claim
15 words
A device as in claim 1 wherein said device is contained within a polymeric matrix.
Claim 7
Dependent Claim
13 words
A device as in claim 5 wherein the matrix comprises ethylene-vinyl acetate copolymer.
Claim 8
Dependent Claim
16 words
A device as in claim 6 wherein said device system is contained within a bioerodable polymer.
Claim 9
Dependent Claim
25 words
A device as in claim 7 wherein the bioerodable polymer is selected from the group consisting of polyanhydrides, polyactic acids, polyglycolic acids and copolymers thereof.
Claim 10
Dependent Claim
62 words
A reservoir sustained release device for the sustained release of fibroblast-derived growth factors which comprises: a. a biocompatible substrate of cross-linked dextran beads having heparin or heparin sulfate bound thereto and the growth factor bound to the heparin or heparin-sulfate; b. a sodium alginate solution surrounding the growth-factor-bound substrate; and c. a hardened sodium alginate envelope surrounding the solution and growth-factor-bound substrate.
Claim 11
Dependent Claim
62 words
A reservoir sustained release device for the sustained release of fibroblast-derived growth factors which comprises: a. a biocompatible substrate of cross-linked dextran beads having heparin or heparin sulfate bound thereto and the growth factor bound to the heparin or heparin-sulfate; b. a sodium alginate solution surrounding the growth-factor-bound substrate; and c. a hardened sodium alginate envelope surrounding the solution and growth-factor-bound substrate.
Claim 12
Dependent Claim
59 words
A matrix sustained release device for the sustained release of fibroblast-derived growth factors which comprises: a. a biocompatible substrate of polymer beads having heparin or heparin sulfate bound thereto and the growth-factor-bound to the heparin or heparin sulfate; and b. a polymeric matrix acting as a supporting framework having a plurality of interconnecting channels which house the growth-factor-bound substrate.
Claim 13
Dependent Claim
59 words
A matrix sustained release device for the sustained release of fibroblast-derived growth factors which comprises: a. a biocompatible substrate of polymer beads having heparin or heparin sulfate bound thereto and the growth-factor-bound to the heparin or heparin sulfate; and b. a polymeric matrix acting as a supporting framework having a plurality of interconnecting channels which house the growth-factor-bound substrate.
References Cited (Backward Citations)
US3645852A
Cited
US4464468A
Cited
US3746621A
Cited
US3647630A
Cited
US3730841A
Cited
US4070348A
Cited
US4038140A
Cited
US4138292A
Cited
US4137127A
Cited
US4164560A
Cited
US4373023A
Cited
US4407957A
Cited
US4678671A
Cited
EP0086186A1
Cited
US4613665A
Cited
US4786501A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1995-03-31 | 1995-09-30 | 1996-03-31 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1999-03-31 | 1999-09-30 | 2000-03-31 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2003-03-31 | 2003-09-30 | 2004-03-31 | $7700.00 | Window Closed / Lapsed |